Vancomycin resistance in staphylococci

Drug Resistance Updates

Volumn 1, Issue 2, 1998, Pages 135-150

  Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001093619     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80029-0     Document Type: Review

References (138)

1. Edmond M.B., Wenzel R.P., and Paxculle A.W. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Annals of Int Med 124 (1996) 329-334
2. Lyon B., and Skurray R. Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiological Reviews 51 (1987) 88-134
3. Hori S., Ohshita Y., Utsui Y., and Hiramatsu K. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob Agents Chemother 37 (1993) 2278-2284
4. Fukuda H., Hori S., and Hiramatsu K. The grlA mutation in norfloxacin-resistant first-step mutants and clinical isolates of Staphyloccus aureus. J Infect Chemother 2 (1996) 98-101
5. Jevons M.P. 'Celbenin'-resistant staphylococci. British Medical Journal 1 (1961) 124-125
6. Tanaka T., Okuzumi K., Iwamoto A., and Hiramatsu K. A retrospective study on methicillin-resistant Staphyloccus aureus clinical strains in Tokyo University Hospital. J Infect Chemother 1 (1995) 40-49
7. Matsuhashi M., Song M.D., Ishino F., Wachi M., Doi M., Inoue M., Ubukata K., Yamashita N., and Konno M. Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. Journal of Bacteriology 167 (1986) 975-980
8. Song M.D., Wachi M., Doi M., Ishino F., and Matsuhashi M. Evolution of an inducible penicillin-target protein in mechicillin-resistant Staphylococcus aureus by gene fusion. FEBS Letter 221 (1987) 167-171
9. Hartman B.J., and Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. Journal of Bacteriology 158 (1984) 513-516
10. Reynolds P.E., and Fuller C. Methicillin-resistant strains of Staphyloccus aureus; presence of identical additional penicillin-binding protein in all strains examined. FEMS Microbiological Letter 33 (1986) 251-254
11. Utsui Y., and Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 28 (1985) 397-403
12. Beck W.D., Berger-Bachi B., and Kayser F.H. Additional DNA in methicillin-resistant Staphylococcus aureus and molecular cloning of mec-specific DNA. Journal of Bacteriology 165 (1986) 373-378
13. Hiramatsu K. Molecular evolution of MRSA. Microbiology and Immunology 39 (1995) 531-543
14. Ryffel C., Bucher R., Kayser F.H., and Berger-Bachi B. The Staphylococcus aureus mec determinant comprises an unusual cluster of direct repeats and codes for a gene product similar to the Escherichia coli sn-glycerophosphoryl diester phosphodiesterase. Journal of Bacteriology 173 (1991) 7416-7422
15. Kreiswirth B., Kornblum J., Arbeit R.D., Eisner W., Maslow J.N., McGee A., Low D.E., and Novick R.P. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science 259 (1993) 227-230
16. Lacey R.W., and Grinsted J. Genetic analysis of methicillin-resistant strains of Staphylococcus aureus: evidence for their evolution from a single clone. J Med Microbiol 6 (1973) 511-526
17. Hiramatsu K. Genetic basis for molecular epidemiology of MRSA. Journal of Infection and Chemotherapy 2 (1996) 117-129
18. Yoshida T., Kondo N., Abu Hanifah Y., and Hiramatsu K. Combined use of ribotyping, PFGE typing and IS431 typing in the discrimination of nosocomial strains of methicillin-resistant Staphylococcus aureus. Microbiol Immunol 41 (1997) 687-695
19. in Japanese. Hashimoto H., Inoue M., and Hayashi I. A survey of Staphylococcus aureus for typing and drug-resistance in varius areas of Japan during 1992 and 1993. Japanese Journal of Antibiotics 47 (1994) 618-626
20. Hiramatsu K., Aritaka N., Hanaki S., Kawasaki S., Hosoda Y., Hori S., Fukuchi Y., and Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350 (1997) 1668-1671
21. Cynamon M.H., and Granto P.A. Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci. Antimicrob Agents Chemother 21 (1982) 504-505
22. Pallanza R., Berti M.B., Goldstein P., Mapelli E., Randisi E., Scotti R., and Arioli V. Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics. J Antimicrob Chemother 11 (1983) 419-425
23. Tuazon C.U., and Miller H. Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci. Antimicrob Agents Chemother 25 (1984) 411-412
24. Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., Verhaegen J., and De Schepper P.J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 26 (1984) 881-886
25. Fainstein V., LeBlanc B., and Bodey G.P. Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother 23 (1983) 497-499
26. Wilson A., O'Hare M.D., Felmingham D., and Gruneberg R.N. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet ii (1986) 973
27. Arioli V., and Pallanza R. Teicoplanin-resistant coagulase-negative staphylococci. Lancet ii (1987) 39
28. Del Bene V.E., John J.F., Twitty J.A., and Lewis J. Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance. J Infect Dis 154 (1986) 349-352
29. Grant A.C., Lacey R., Brownjohn A.M., and Turney J.H. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet ii (1986) 1166-1167
30. Moore E.P., and Speller D. In vitro teicoplanin resistance in coagulase negative staphylococci from patients with endocarditis and from a cardiac surgery unit. J Antimicrob Chemother 21 (1988) 417-424
31. Maugein J., Pellegrin J.L., Brossard G., Fourche J., Leng B., and Reiffers J. In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob Agents Chemother 34 (1990) 901-903
32. Vedel G., Leruez M., Lemann F., Hraoui E., and Ratovohery D. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. Eur J Clin Microbiol Infect Dis 9 (1990) 820-822
33. Mouton R.P., and Mulders S.L. LY 146032: activity and resistance development in vitro. J Antimicrob Chemother 20 (1987) 513-517
34. Watanakunakorn C. In vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin. Journal of Antimicrobial Chemotherapy 22 (1988) 321-324
35. Watanakunakorn C. In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 25 (1990) 69-72
36. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. Journal of Antimicrobial Chemotherapy 14 Suppl. D (1984) 7-18
37. Chomarat M., Espinouse D., and Flandrois J.-P. Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity. J Antimicrob Chemother 27 (1991) 475-480
38. Parenti F., Beretta G., Berti M., and Arioli V. Teichomycin, new antibiotics from Actinoplanes teichomyceticus, nov. sp. I. Description of the producer strain, fermentation studies and biological properties. J Antibiot 31 (1978) 276-281
39. Griffith R.S. Vancomycin use - an historical review. J Antimicrob Chemother 14 Suppl. D (1984) 1-5
40. Schwalbe R.S., Stapleton J.T., and Gilligan P.H. Emergence of vancomycin resistance in coagulase-negative staphylococci. New England Journal of Medicine 316 (1987) 927-931
41. Schwalbe R.S., Ritz W.J., Verma P.R., Barranco E.A., and Gilligan P.H. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis 161 (1990) 45-51
42. Froggatt J.W., Johnston J.L., Galetto D.W., and Archer G.L. Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother 33 (1989) 460-466
43. Veach L.A., Pfaller M.A., Barrett M., Koontz F.P., and Wenzel R.P. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. Journal of Clinical Microbiology 28 (1990) 2064-2068
44. Sanyal D., Johnson A.P., George R.C., Cookson B.D., and Williams A.J. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet 337 (1991) 54
45. Kaatz G., Seo S.M., Dorman N.J., and Lerner S.A. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 162 (1990) 103-108
46. Shlaes D.M., and Shalaes D.H. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clinical Infectious Diseases 20 (1995) 1071-1072
47. Bailey E.M., Rybak M.J., and Kaatz G.W. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 35 (1991) 1089-1092
48. Serzin V., Mougeot C., and Libert J.M. Methicillin-resistant Staphylococcus aureus and glycopeptides: in vitro selection of resistance. Path Biol 42 (1994) 323-327
49. Brunet G., Vedal G., Dreyfus F., Vaxelaire J.F., Giraud T., Schremmer B., and Mosallier J.F. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbial Infect Dis 9 (1990) 145-147
50. Mainardi J.-L., Shlaes D.M., Goering R.V., Shlaes J.H., Acar J.F., and Goldstein F.W. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 171 (1995) 1646-1650
51. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40 (1997) 135-136
52. CDC. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity Mortality Weekly Report 46 (1997) 765-766
53. CDC. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity Mortality Weekly Report 46 (1997) 813-815
54. in press. Tenover F.C., Lancaster M.V., Hill B.C., Steward C.D., Stocker S.A., Hancock G.A., O'Hara C.M., Clark N.C., and Hiramatsu K. Characterization of staphylococci with reduced susceptibility to vancomycin and other glycopeptides. Journal of Clinical Microbiology (1998)
55. Barber M. Naturally occurring methicillin-resistant staphylococci. J Gen Microbiol 35 (1964) 183-190
56. Dyke K.G.H. Penicillinase production and intrinsic resistance to penicillins in methicillin-resistant cultures of Staphylococcus aureus. J Med Microbiol 2 (1969) 261-278
57. Sabath L.D., and Wallace S.J. Factors influencing methicillin resistance in staphylococci. Ann New York Acad Sci 182 (1971) 258-266
58. Asada K., Inaba Y., Tateda-Suzuki E., et al. Evolution and resistance expression of MRSA; evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. Acta Biochimica Polonica 42 (1995) 517-524
59. Ryffel C., Strassle A., FH K., and Berger-Bachi B. Mechanism of heteroresistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 38 (1994) 724-728
60. Kuwahara-Arai K., Kondo N., Hori S., Tateda-Suzuki E., and Hiramatsu K. Suppression of methicillin resistance in a mecA-containing premethicillin-resistant Staphylococcus aureus strain is caused by the mecl-mediated repression of PBP2' production. Antimicrobial Agents and Chemotherapy 40 (1996) 2680-2685
61. Hiramatsu K., Asada K., Suzuki E., Okonogi K., and Yokota T. Molecular cloning and nucleotide sequence determination of the regulator region of mecA gene in methicillin-resistant Staphylococcus aureus (MRSA). FEBS Letter 298 (1991) 133-136
62. Tesch W., Ryffel C., Strassle A., Kayser F.H., and Berger-Bachi B. Evidence of a novel staphylococcal mec-encoded element (mecR) controlling expression of penicillin-binding protein 2′. Antimicrob Agents Chemother 34 (1990) 1703-1706
63. Tomasz A., Nachman S., and Leaf H. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 35 (1991) 124-129
64. Hiramatsu K., Asada K., Suzuki E., and Yokota T. Methicillin resistance regulation of the prototype MRSA strain N315. In: Mollby R., Flock J.-I., Nord C.E., and Christensson B. (Eds). Staphylococci and Staphylococcal Infections (1994), Gustav Fischer Verlag 191-193
65. Courvalin P. Resistance of enterococci to glycopeptides. Antimicrobial Agents and Chemotherapy 34 (1990) 2291-2296
66. Swenson J.M., Clark N.C., Ferraro M.J., Sahm D.F., Doern G., Pfaller M.A., Reller L.B., Weinstein M.P., Zabransky R.J., and Tenover F.C. Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol 32 (1994) 1700-1704
67. LB-15. Boyce J.M., Medeiros A.A., and Hiramatsu K. Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) from the United States with subpopulations of cells with reduced suseptibility to vancomycin. 37th Intersci Conf Antimicrob Agents Chemother abstr. (1997)
68. Arthur M., and Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37 (1993) 1563-1571
69. Spratt B.G. Distinct penicillin-binding proteins involved in the division, elongation, and shape of Escherichia coli K-12. Proc Natl Acad Sci USA 72 (1975) 2999-3003
70. Dougherty T.J., Kennedy K., Kessler R.E., and Pucci M.J. Direct quantitation of the number of individual penicillin-binding proteins per cell in Escherichia coli. J Bacteriol 178 (1996) 6110-6117
71. Bremer H., and Dennis P.P. Modulation of chemical composition and other parameters of the cell by growth rate. In: Neidhardt F.C., et al. (Ed). Escherichia coli and Salmonella. 2nd ed vol. 2 (1996), ASM Press, Stuttgart 1553-1569
72. Reynolds P.E. Structure, biochiemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8 (1989) 943-950
73. Snowden M.A., and Perkins H.R. Peptidoglycan cross-linking in Staphylococcus aureus. Eur J Biochem 191 (1990) 373-377
74. Van Heijenoort J. Biosynthesis of the bacterial peptidoglycan unit. In: Ghuysen J.-M., and Hakenbeck R. (Eds). Bacterial cell wall (1994), Elsevier Science BV, Washington, DC 39-54
75. Greenwood D. Microbiological properties of teicoplanin. J Antimicrob Chemother 21 Suppl. A (1988) 1-13
76. Chambers H.F. Parenteral antibiotics for the treatment of bacteremia and other serious Staphylococcal infections. In: Crossley K.B., and Archer G.L. (Eds). The staphylococci in human disease (1996), Churchill Livingstone 583-601
77. Yoshida T., and Hiramatsu K. Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus (MRSA). Microbiol Immunol 37 (1993) 853-859
78. Chambers H.F., and Sande M.A. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 26 (1984) 61-64
79. Levine D.P., Fromm B.S., and Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. An Int Med 115 (1991) 674-680
80. Gopal V., Bisno A.L., and Silverblatt F.J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. JAMA 236 (1976) 1604-1606
81. Tomasz A., Albino A., and Zanati E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 227 (1970) 138-140
82. Sabath L.D., Wheeler N., Laverdiere M., Blazevic D., and Wilkinson B.J. A new type of penicillin resistance of Staphylococcus aureus. Lancet i (1997) 443-447
83. Sorrell T.C., Packham D.R., Shanker S., Foldes M., and Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. An Int Med (1982) 344-350
84. Nakatani T. Pharmacokinetic study in respiratory infection. Antibiot Chemother 10 (1994) 425-432
85. Niitsuma K., and Saito M. Vancomycin inhalation therapy - a pharmacokinetic and clinical study of vancomycin. Antibiot Chemother 12 (1996) 123-135
86. Shimada K., Kobayashi H., Sunakawa K., Inamatsu T., and Yamaguchi K. Clinical summary of intravenous use of vancomycin hydrochloride for severe infection caused by methicillin-resistant Staphylococcus aureus. Chemother 43 (1995) 1048-1061
87. Torres J.R., Sanders C.V., and Lewis A.C. Vancomycin concentration in human tissues: preliminary report. J Antimicrob Chemother 5 (1979) 475-477
88. Nakashima M., Katagiri K., and Oguma T. Phase I studies on vancomycin hydrochloride for injection. Chemother 40 (1992) 210-224
89. Milliken S.P., Matzke G.R., and Keane W.F. Antimicrobial treatment of peritonitis associated with continous ambulatory peritoneal dialysis. Perit Dial Int 11 (1991) 252-260
90. Buggy B.P., Schaberg B.P., and Swartz R.D. Intraleukocytic sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. Am J Med 76 (1984) 1035-1040
91. (Suppl.). Casewell M.W. New threats to the control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 30 (1995) 465-471
92. Leclercq R., Derlot E., Weber M., Duval J., and Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother 33 (1989) 10-15
93. Quintiliani Jr. R., Evers S., and Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 167 (1993) 1220-1223
94. Recsei P.A., Gruss A.D., and Novick R.P. Cloning, sequence and expression of the lysostaphin gene from Staphyloccus simulans. Proc Natl Acad Sci USA 84 (1987) 1127-1131
95. Fontana R., Ligozzi M., Pedrotti C., Padovaniem E.M., and Cornaglia G. Vancomycin-resistant Bacillus circulans carrying the vanA gene responsible for vancomycin resistance in enterococci. Eur J Clin Microbiol Infect Dis 16 (1997) 473-474
96. Noble W.C., Virani Z., and Cree R. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTCl2201 to Staphylococcus aureus. FEMS Microbiological Letter 93 (1992) 195-198
97. Daum R.S., Gupta S., Sabbagh R., and Milewski W.M. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. Journal of Infectious Diseases 166 (1992) 1066-1072
98. Sieradzki K., and Tomasz. A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiological Letter 142 (1996) 161-166
99. Dutka-Malen S., Leclercq R., Coutant V., Duval J., and Courvalin P. Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 34 (1990) 1875-1879
100. in press. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. American Journal of Medicine (1998)
101. in Japanese 1998. Hanaki H., Labischinski H., Sasaki K., Kuwahara-Arai K., Inaba Y., and Hiramatsu K. Mechanism of vancomycin resistance in MRSA strain Mu50. Japanese Journal of Antibiotics 51 (1998) 237-247
102. in press, in Japanese. Hanaki H., Labischinski H., Inaba Y., and Hiramatsu K. Increase of nonamidated muropeptides in the cell wall of vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50. Japanese Journal of Antibiotics (1998)
103. Nakel M., Ghuysen J.-M., and Kandler O. Wall peptidoglycan in Aerococcus viridans strains 201 Evans and ATCC I 1563 and in Gaffkya homari strain ATCC 10400. Biochemistry 10 (1971) 2170-2175
104. Stranden A.M., Roos M., and Berger-Bachi B. Glutamine synthetase and heteroresistance in methicillin-resistant Staphylococcus aureus. Microb Drug Res 2 (1996) 201-207
105. Moreira B., Boyle-Vavra S., De Jonge B.L.M., and Daum R. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 41 (1997) 1788-1793
106. Mackay J.P., Gerhard U., Beauregard D.A., Westwell M.S., Searle M.S., and Williams D.H. Glycopeptide antibiotic activity and the possible role of dimerization: a model for biological signaling. J Am Chem Soc 116 (1994) 4581-4590
107. Beauregard D.A., Williams D.H., Gwynn M.N., and Knowles D.J.C. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother 39 (1995) 781-785
108. Somma S., Gastaldo L., and Corti A. Teicoplanin, a new antibiotic from Actinoplanes teicomyceticus nov. sp. Antimicrob Agents Chemother 26 (1984) 917-923
109. Shlaes D.M., Shlaes J.H., Vincent S., Etter L., Fey P.D., and Goering R.V. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrobial Agents and Chemotherapy 37 (1993) 22432-22437
110. Murakami K., Fujimura T., and Doi M. Nucleotide sequence of the structural gene for the penicillin-binding protein 2 of Staphylococcus aureus and the presence of a homologous gene in other staphylococci. FEMS Microbiological Letter 117 (1994) 131-136
111. Okonogi K., Noji Y., Nakao M., and Imada A. The possible physiological roles of penicillin-binding proteins of methicillin-susceptible and -resistant Staphylococcus aureus. Journal of Infection and Chemotherapy 1 (1995) 50-58
112. Park W., and Matsuhashi M. Staphylococcus aureus and Micrococcus luteus peptidoglycan transglycosylases that are not penicillin-binding proteins. Journal of Bacteriology 157 (1984) 538-544
113. O'Hare M.D., and Reynolds P.E. Novel membrane proteins present in teicoplanin-resistant, vancomycin-sensitive, coagulase-negative Staphylococcus spp. J Antimicrob Chemother 30 (1992) 753-768
114. Billot-Klein D., Gutmann L., Bryant D., Bell D., van Heijenoort J., Grewal J., and Shlaes D.M. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. J Bacteriol 178 (1996) 4696-4703
115. Herwaldt L., Boyken L., and Pfaller M. In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 10 (1991) 1007-1012
116. Sanyal D., Johnson A.P., George R.C., Edwards R., and Greenwood D. In-vitro characteristics of glycopeptide resistant strains of Staphylococcus epidermidis isolated from patients on CAPD. J Antimicrobial Chemotherapy 32 (1993) 267-278
117. Biavasco F., Giovanetti E., Montanari M.P., et al. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother 27 (1991) 71-79
118. Giovanetti E., Biavascoo F., Pugnaloni A., Lupidi R., Biagini G., and Varaldo P.E. An electron microscopic study of clinical and laboratory-derived strains of teicoplanin-resistant Staphylococcus haemolyticus. Microb Drug Res 2 (1996) 239-243
119. Cercenado E., Garcia-Leoni M.E., Diaz M.D., Sanchez-Carrillo C., Catalan P., Bernaldo De Quiros J.C.L., and Bouza E. Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol 34 (1996) 1765-1768
120. Goldstein F.W., Coutrot A., Sieffer A., and Acar J.F. Percentages and distribution of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 34 (1990) 899-900
121. Woodford N., Johnson A.P., Morrison D., and Speller D. Current perspective on glycopeptide resistance. Clin Microbiol Rev 8 (1995) 585-615
122. +-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 40 (1996) 166-172
123. +-dependent D-Lactate dehydrogenase and insertional inactivation in a glycopeptide-resistant isolate. Journal of Bacteriology 179 (1997) 6756-6763
124. Sieradzki K., and Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 179 (1997) 2557-2566
125. in Japanese. Hanaki H., and Hiramatsu K. Evaluation of reduced vancomycin susceptibility of MRSA strain Mu50 with various conditions of antibiotic susceptibility tests. Japanese Journal of Antibiotics 50 (1997) 794-798
126. Hanaki H., Akagi H., Yasui M., Otani T., Hyodo A., and Hiramatsu K. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 39 (1995) 1120-1126
127. Fass R.J. In vitro activity of RP59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 35 (1991) 553-559
128. Kaatz G.W., and Seo S.M. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 40 (1996) 799-801
129. Jones R.N., and Barrett M.S. Antimicrobial activity of SCH27899, oligosaccharide member of the everninomycin class with a wide gram-positive spectrum. J Clin Microbiol Infect 1 (1995) 35
130. Korten V., Tomayko J.F., and Murray B.E. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrob Agents Chemother 38 (1994) 611-615
131. abstr B-30b. Climo M., Patron R.L., Hale-Cooper C.G., Goldstein B., Markowitz S.M., and Archer G. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus in the rabbit model of endocarditis. 37th Intersci Conf Antimicrob Agents Chemother (1997)
132. in Japanese. Tabata M., Takada T., Hirano F., and Hiramatsu K. Combined bacteriocidal effect of arbekacin and sulbactam/ampicillin on MRSA. Deutsche Medizinische Worchenschrift 18 (1996) 1549-1552
133. Matsuhashi Y., and Yamamoto H. The enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillin-cephemresistant Staphyloccus aureus. Jpn J Antibiot 41 (1988) 523-529
134. Watanabe T., Ohashi K., Matsui K., and Kubota T. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 39 (1997) 471-476
135. Chambers H.F., and Sachdeva M. Binding of beta-lactam antibiotics to pencillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infectious Dis 161 (1990) 1170-1176
136. Chambers H.F., Kartalija M., and Sande M. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis 171 (1995) 897-902
137. Galetto D.W., Boscia J.A., Kobasa W.D., and Kaye D. Teicoplanin compared with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J Infect Dis (1986)
138. Walsh T.J., Auger F., Tatem B.A., Hansen S.L., and Standiford H.C. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin. J Antimicrob Chemother 17 (1986) 75-82